PD-1 Fatigue: Cross-Labeling May Help Pare Checkpoint Inhibitor Pipeline

 
• By Laura Helbling
  
Watch gears up close
The US FDA wants firms' PD-1 trials to mesh together well.

More from Approval Standards

More from Pathways & Standards